This website uses cookies to ensure you get the best experience on our website.
- Table of Contents
CYP27A1 · Western blot design guide
CYP27A1 Western Blot Planning Guide
Plan a CYP27A1 Western blot around the catalog-observed 60.2 kDa band, image-backed A02121-2 evidence, HPA controls, and verified protocol records.
Evidence assembled July 2026 · For research use; verify linked source records and product datasheet before use
CYP27A1 Western Blot Experimental Design Guide
Expected bands, documented protocol parameters, controls and antibodies — the at-a-glance facts below, then the full design guide.
Must know before running
| Expected band | 60.2 kDa | |
| Observed band | Not reported — verify product WB image | |
| Gel | 12-15% | |
| Positive control | Lung | |
| Negative control | Bone marrow |
Important caveats
Reasons your observed band may differ from the expected size.
| ⓘ | Calculated mass | 60.2 kDa |
| ⓘ | Localization | Mitochondrion inner membrane |
| ⓘ | Processing / PTM | Record-dependent |
| ⓘ | Reactivity | Human / Mouse / Rat |
Section 1
Real Curated CYP27A1 Western Blot Protocols
Start with the molecular-weight rule, then compare verified publication-derived conditions.
| Sample / lysate | Adrenal gland |
| Gel % | 12-15% |
| Load | 20-30 µg total protein per lane |
| Transfer | Semi-dry, standard transfer |
| Membrane | 0.45 µm PVDF |
| Blocking | 5% non-fat milk or 5% BSA in TBST |
| Primary | A02121-2 at datasheet starting dilution |
| Primary incubation | Overnight at 4 °C with gentle agitation |
| Secondary | Species-matched HRP conjugate at validated dilution |
| Wash | 3 × 5 min in TBST |
| Detection | Chemiluminescent substrate |
| Exposure | Bracket exposures to avoid saturation |
Section 2
What Is the Expected CYP27A1 Western Blot Band Size?
Use the product-observed 60.2 kDa band as the primary planning value and retain the UniProt calculated mass as context.
| 60.2 kDa | Matches the authoritative product WB observation. |
| 60.2 kDa calculated | Use as UniProt context, not as a replacement observed band. |
| Unexpected additional signal | Do not assign identity without orthogonal positive/negative controls. |
💡Expected CYP27A1 appearancePlan around 60.2 kDa and keep the calculated mass as supporting context.
| Catalog-observed band | 60.2 kDa; use this as the primary experimental expectation. |
| Calculated mass | 60.2 kDa from UniProt Q02318; retain as context. |
| Gel selection | 12-15%; shared with the recommended protocol and poster. |
| Specificity check | Compare the lead HPA positive and negative controls with A02121-2. |
| Situation | Likely cause | Next action |
|---|---|---|
| 60.2 kDa | Matches the authoritative product WB observation. | Confirm with orthogonal controls and the linked product record. |
| Additional band | May reflect processing, modification, or non-specific signal. | Run a dilution series and compare positive/negative controls. |
| Weak signal | Target abundance or transfer may be limiting. | Verify transfer, increase positive-control abundance, and bracket exposure. |
Experiment evidence
Western blot images showing CYP27A1 band
A02121-2 · CYP27A1
← swipe / scroll for more images →
Real WB data behind the band-size expectations in this section.
Sample controls for CYP27A1 Western blot
🧪Use Lung as the first positive-control candidate and Bone marrow as the HPA Not detected negative candidate.
Positive control: Lung (High)
Negative control: Bone marrow (Not detected)
HPA protein score determines control status; other expression data is supporting context only.
HPA tissue expression evidence for CYP27A1
Comprehensive Human Protein Atlas IHC scoring per tissue. Rows are taken directly from the HPA tissue chart — click any row's HPA link to view the source.
Positive expression · recommended positive controls
| Tissue | Cell type | Level | Evidence | Source |
|---|---|---|---|---|
| Lung | Reported tissue cells | High | Protein (HPA) | HPA → |
| Adrenal gland | Reported tissue cells | High | Protein (HPA) | HPA → |
| Kidney | Reported tissue cells | High | Protein (HPA) | HPA → |
| Bronchus | Reported tissue cells | High | Protein (HPA) | HPA → |
Section 3
Advanced CYP27A1 Western Blot Tips
Deeper troubleshooting and optimisation questions for CYP27A1, answered from its protein features.
Which band should guide the blot?
Use 60.2 kDa, the observation attached to the authoritative A02121-2 WB record.
How should calculated mass be interpreted?
Treat the UniProt calculated mass as context; it does not replace the catalog-observed 60.2 kDa expectation.
Which positive control should I start with?
Start with Lung, the lead HPA protein-expression candidate.
Which negative control is defensible?
Use Bone marrow as an orthogonal HPA Not detected candidate.
Which gel should I use?
Use 12-15% consistently across the quick facts, protocol table, and poster.
What transfer method to use for CYP27A1 Western blot?
Use the transfer method in the recommended protocol and verify transfer before blocking.
How should A02121-2 be started?
Start at the linked datasheet condition and run a three-point primary-antibody dilution test.
Which publication-derived protocols can I compare?
No verified publication protocol was supplied; use only the deterministic recommended protocol.
Boster reagents
CYP27A1 Western Blot Reagents
Human/Mouse/Rat-reactive CYP27A1 Western blot reagents with authoritative product imagery.
Real WB data
Anti-CYP27A1 Antibody Picoband®
Cat # A02121-2
Only image-backed, WB-validated Human/Mouse/Rat recommendations from the prepared catalog evidence are shown.
Source: prepared picoband-wb product evidence; each card retains its own SKU, URL, observed band, and authoritative WB image.
References
- UniProt Q02318
- Human Protein Atlas — CYP27A1
- A02121-2 product record
- PMC6159944 — Silencing carboxylesterase 1 in human THP-1 macrophages perturbs genes regulated by PPARγ/RXR and RAR/RXR: down-regulation of CYP27A1-LXRα signaling (The Biochemical journal, 2018)
- PMC6036494 — miR-204 functions as a tumor suppressor gene, at least partly by suppressing CYP27A1 in glioblastoma (Oncology letters, 2018)
- PMC9506397 — Hydroxychloroquine Effects on THP-1 Macrophage Cholesterol Handling: Cell Culture Studies Corresponding to the TARGET Cardiovascular Trial (Medicina (Kaunas, Lithuania), 2022)
